Cerbios' Senior Scientist on Antibody Drug Conjugates

GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study

ABCDx, a leader in brain injury diagnostics, is proud to announce the acceptance of the article, "Heart-type fatty acid binding protein as a biomarker in transient ischemic attack," for publication in the prestigious journal, Cardiovascular Translational Research. This pivotal study highlights the innovative use of Heart-type Fatty Acid Binding Protein (H-FABP) as a diagnostic biomarker for Transi

Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. Preparation for the Phase II tria

The 5-HT3 receptor (5-HT3R) is a member of the Cys-loop family of ligand-gated ion channels, which are in both the peripheral and central nervous systems. 5-HT3R is involved in regulation of neurotransmitter systems implicated in the pathophysiology of major depression. In this work, AlphaMol collaborated with Max Planck Institute, discovered that different from traditional homopentamer, 5-TH3R co

By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs